PRISM: An Open-label, Multi-Center Extension Study to Investigate the Efficacy and Safety of Cobomarsen (MRG-106) Following Systemic Treatment in Subjects With Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides (MF) Subtype, Who Have Completed the SOLAR Study
Latest Information Update: 03 Aug 2022
At a glance
- Drugs Cobomarsen (Primary)
- Indications Cutaneous T-cell lymphoma; Mycosis fungoides
- Focus Therapeutic Use
- Acronyms PRISM
- Sponsors miRagen Therapeutics; Viridian Therapeutics
Most Recent Events
- 17 Nov 2020 Status changed from recruiting to discontinued.
- 05 Sep 2020 This trial has been completed in spain as per European Clinical Trials Database record.
- 30 Aug 2020 This trial has been discontinued in Austria, as per European Clinical Trials Database record.